Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

Employees

Sector

Pharmaceuticals

More about the company

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.860EUR

Average target price

9.265EUR

Spread / Average Target

+398.12%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI

Market Cap	46.1M 52.53M 43.54M 39.68M 74.27M 5.03B 74.8M 521M 202M 2.57B 197M 193M 8.27B	P/E 2026 *	-3x	P/E 2027 *	-2.82x
Enterprise Value	38.8M 44.21M 36.64M 33.39M 62.51M 4.24B 62.95M 438M 170M 2.16B 166M 162M 6.96B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	68.98%	Yield 2026 *	-	Yield 2027 *	-

08-06	Pentixapharm Holding AG Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-06	Pentixapharm Holding AG and Pentixapharm AG Announce Executive Changes	CI
08-06	Pentixapharm Holding Ag Reaffirms Earnings Guidance for the Full Year 2026	CI
07-22	Pentixapharm Raises EUR16.8 Million via Rights Offering	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-22	Eckert & Ziegler next in BaFin's sights, shares rebound	DP
07-22	Eckert & Ziegler Faces BaFin Review Over Pentixapharm Spin-off Accounting	MT
07-22	Eckert & Ziegler: BaFin reviews 2024 financial statements over Pentixapharm spin-off	DP
07-09	Pentixapharm Holding AG Receives FDA Fast Track Designation For Phase 3 Diagnostic Candidate [68Ga]Ga-Pentixafor In Primary Aldosteronism	CI
07-09	Pentixapharm's Underdevelopment Radiodiagnostic Gets Fast Track Designation From US FDA	MT
06-09	Pentixapharm Disputes German Regulator's Preliminary Error Findings in FY24 Financial Statements	MT
06-09	Pentixapharm Holding Ag Announces Fda Clearance of Ind for Phase 3 Panda Study of First-In-Class Cardiovascular Diagnostic Program	CI
06-09	Pentixapharm Gains US FDA Clearance for Late-stage PentixaFor Study	MT

08-17	Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Purchase of shares by exercising subscription rights	EQ
08-06	Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program	EQ
07-27	Pentixapharm Completes Capital Increase – New Shares Placed in Full	EQ
07-27	Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today	EQ
07-23	Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement	AQ

Pentixapharm Holding AG Stock OTC Markets

Stocks

PTPDF

DE000A40AEG0

Pharmaceuticals

Valuation: Pentixapharm Holding AG

Latest news: Pentixapharm Holding AG

Press Releases: Pentixapharm Holding AG

News in other languages: Pentixapharm Holding AG

Price Extremes

Other Pharmaceuticals

Financials

Company Profile

Analysts' Consensus

Annual profits - Rate of surprise

Current year	0		2.31
1 year	0		2.31
3 years	0		2.31
5 years	0		2.31
10 years	0		2.31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PENTIXAPHARM HOLDING AG	-.--%	-.--%	-	-	53.25M
ELI LILLY AND COMPANY	+0.13%	+2.65%	+65.61%	+114.28%	1,053B
JOHNSON & JOHNSON	+0.20%	+0.46%	+52.60%	+69.24%	652B
ABBVIE INC.	-0.29%	+0.14%	+20.96%	+70.93%	468B
ROCHE HOLDING AG	-0.85%	-0.25%	+38.63%	+44.47%	351B
NOVARTIS AG	+0.71%	+3.26%	+22.46%	+30.30%	273B
ASTRAZENECA PLC	+1.23%	+1.00%	+11.97%	+13.63%	254B
AMGEN INC.	+2.11%	+7.51%	+52.89%	+55.37%	220B
GILEAD SCIENCES, INC.	+0.83%	+0.55%	+35.99%	+101.70%	186B
NOVO NORDISK A/S	0.00%	-9.43%	-31.91%	-60.56%	170B
Average	+0.34%	+0.30%	+29.91%	+48.82%	403.04B
Weighted average by Cap.	+0.22%	+1.00%	+41.03%	+68.05%

	2026 *	2027 *
Net sales	-	-
Net income	-22.3M -25.41M -21.06M -19.19M -35.93M -2.44B -36.19M -252M -97.62M -1.24B -95.42M -93.35M -4B	-23.5M -26.78M -22.19M -20.23M -37.86M -2.57B -38.13M -266M -103M -1.31B -101M -98.38M -4.21B
Net Debt	-7.3M -8.32M -6.89M -6.28M -11.76M -797M -11.85M -82.5M -31.96M -407M -31.23M -30.56M -1.31B	12.3M 14.02M 11.62M 10.59M 19.82M 1.34B 19.96M 139M 53.84M 686M 52.63M 51.49M 2.21B